A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical.

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

R5 洪逸平 SUPERVISOR 趙大中醫師. Breast Cancer  The most prevalent cancer in female  Mortality 4 th in Taiwan.

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Date Name Speaker Institute / University. Raman4Clinics – Raman-Based Applications for Clinical Diagnostics Based on Raman Spectroscopy and to overcome.

Clinical Utility of CellSearch Richard A. Bender,MD,FACP Medical Director-Hematology/Oncology Quest Diagnostics Nichols Institute.

Isolation of Rare Circulating Tumor Cells in Cancer Patients by Microchip Technology Toner, et al Stephanie Bachar Matt Luchette.

Isolation of Rare Circulating Tumor Cells Sunitha Nagrath et al. Presentation.

Isolation of rare circulating tumor cells in cancer patients by microchip technology Nagrath & Sequist et al. (2007) Journal Presentation Brigitte Morales.

SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.

Evaluating Potential Drug Therapies Mike Shuler Biomedical Engineering.

Biomaterials Science Part II: Materials in Medicine Synthetic Vascular Grafts March 6, 2010 assignment reading: Brett C. Isenberg, Chrysanthi Williams.

Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.

Biomedical Research.

When will the diagnosis of Circulating tumor cells (CTC) help to patients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Laboratory toxicology. Toxicological methods In vitro –Cell cultures –Cell-free systems –Mechanistic In vivo (lab animals) –Acute –Subchronic –Chronic.

Microtube Device for Selectin- Mediated Capture of Viable Circulating Tumor Cells from Blood A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T.

Sunitha Nagrath, Lecia V. Sequist, Shyamala Maheswaran, Daphne W. Bell, Daniel Irimia, Lindsey Ulkus, Matthew R. Smith, Eunice L. Kwak, Subba Digumarthy,

Laser Treated Metallic Probes for Cancer Treatment in MRI Systems July 08, Advance Materials Processing and Analysis Center (AMPAC) Department of.

Phlebotomy Technician Medical Lab Assistant Medical Lab Technician Medical Technologist/Clinical Lab Scientist.

Dr Godfrey Grech University of Malta

肝胆胰腺肿瘤外科 HEPATO-PANCREATO-BILIARY SURGERY 读书汇报科室：肝胆胰腺外二科导师：郝纯毅教授报告人：安启明.

 Gy  Decreased fibrosis  Enhanced local control  Deep seeded tumors isch&source=hp&biw=1366&bih=624&q=radia.

“Isolation of rare circulating tumour cells in cancer patients by microchip technology” Nagrath et al. Nature 2007 Peter Bojo.

Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.

UNIVERSAL SURVIVAL CURVE AND SINGLE FRACTION EQUIVALENT DOSE: USEFUL TOOLS IN UNDERSTANDING POTENCY OF ABLATIVE RADIOTHERAPY CLINT PARK, M.D. M.S., LECH.

AmirAli H. Talasaz, Ashley A. Powell, David E. Huber, James G. Berbee, Kyung-Ho Roh, Wong Yu, Wenzhong Xiao, Mark M. Davis, R. Fabian Pease, Michael N.

Human primary cells These cells taken from living tissue are extremely accurate as they are literally coming from the source and are available from many.

Circulating tumor cell monitoring, isolation and culture from a patient with metastatic triple negative breast cancer for drug screening and creation of.

Understanding Radiation Therapy Lecturer Radiological Science

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Production and clinical development of nanoparticles for gene delivery

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood Michael Mitas, Loretta Hoover, Gerard Silvestri,

Progression After Cancer Immunotherapy in Advanced NSCLC

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

A Critical Evaluation of Clinical Research Study Designs

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches Matthew.

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Kyong-Ah Yoon, Sohee Park, Sang Hee Lee, Jin Hee Kim, Jin Soo Lee

Clinical applications of CTC and ctDNA analyses in cancer care.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine.

Detection of Circulating Lung Cancer Cells with Strong Thymidylate Synthase Reactivity in the Peripheral Blood of a Patient with Pulmonary Adenocarcinoma.

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Molecular prognostication of liver cancer: End of the beginning

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Circulating Tumor Cells and Detection of the Melanoma-Associated Antigen HMW-MAA in the Serum of Melanoma Patients Anja Ulmer, Gerhard Fierlbeck Journal.

SYNOPSIS OF THE PROTOCOL

Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study Noriyoshi Sawabata, MD, Mitsunori.

Journal of Thoracic Oncology

The Role of TIPE2 Protein in Invasive Breast Carcinoma

In vivo effects of TTFields on intradermal tumors in mice.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Supplementary Table 1. TTI-621 binds to human tumor cell lines

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC Phil A.J.

Presentation transcript:

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire Presenter ： Wei-Siang Ciou Adviser ： Dr.Yi-Chun Du Date ： 2014/11/19 IBS_LAB Saucedo-Zeni, N., Mewes, S., Niestroj, R., Gasiorowski, L., Murawa, D., Nowaczyk, P.,... & Lücke, K. (2012). A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. International journal of oncology,41(4),

Outline  Abstract  Introduction  Materials and methods  Results  Discussion IBS_LAB

Abstract (1/2)  Circulating tumor cells  To overcome the limitations of small blood sample volumes of the ex vivo CTC isolation techniques IBS_LAB

 Suitability 、 specificity and sensitivity  Tested in 24 breast cancer or non-small cell lung cancer patients and in 29 healthy volunteers  Found to be safe with no noteworthy side effects Abstract (2/2) IBS_LAB

Introduction (1/4)  Personalized cancer treatment  Improve health and quality of life of cancer patients  Different tumor cells are distinct on the molecular level IBS_LAB

Introduction (2/4)  Circulating tumor cells(CTCs) CTCs detection flow chart 檢測循環腫瘤細胞研究進展.pdf IBS_LAB

Introduction (3/4)  Alternative medical device IBS_LAB

Introduction (4/4)  Photoacoustic flow cytofluorometry  Schematic drawing of an in vitro flow system for repeated interaction of CTC with the FSMW, and cancer cells captured by the FSMW. IBS_LAB

Materials and methods (1/7)  Functionalized structured medical wire  0.5 mm in diameter and 160 mm in length  The first 20 mm are plated with a 2 µm thick gold layer deposited on the device by galvanization  A hydrogel layer composed of a linear IBS_LAB

Materials and methods (2/7)  In vitro experiments IBS_LAB

Materials and methods (3/7)  Principle of peristaltic pump IBS_LAB

Materials and methods (4/7)  Principle of peristaltic pump IBS_LAB

Materials and methods (5/7)  Cytotoxicity tests  Acute systemic toxicity IBS_LAB

Materials and methods (6/7)  Hemocompatibility test  Assessment of the patient's risk to develop thrombosis  Coagulation and Hemolysis after in vivo exposure to the FSMW IBS_LAB

Materials and methods (7/7)  In vivo application of the FSMW IBS_LAB

Result (1/5) IBS_LAB

Result (2/5)  Cancer cells captured by the FSMW IBS_LAB

Result (3/5)  Biocompatibility of the FSMW device A.Teflon wire eluate ： No apparent changes in cell morphology. B.Copper wire eluate ： Severe changes in cell morphology. C.FSMW eluate prepared from a singl FSMW ： No apparent change in cell morphology. D.FSMW eluate prepared from three FSMW: No apparent change in cell morphology. IBS_LAB

Result (4/5)  In vivo application of the FSMW in healthy volunteers and in breast cancer and NSCLC patients IBS_LAB

Result (5/5) IBS_LAB

Discussion (1/3)  The main cause of death from cancer  Most histopathologic studies investigated primary tumor tissues only IBS_LAB

Discussion (2/3)  CTC in the peripheral blood of cancer patients exist in extreme rarity IBS_LAB

Discussion (3/3)  Prospective clinical cancer trials. IBS_LAB

Thanks for Your Attention IBS_LAB